Benitec Biopharma Inc. BNTC · Stock Open Benitec Biopharma Inc. in new tab
Benitec Biopharma Inc. Analysis (BNTC)
Is Benitec Biopharma Inc. a good investment? Benitec Biopharma Inc. (BNTC) is currently trading at 11.02 USD. Market analysts have a consensus price target of 24.17 USD. This suggests a potential upside from current levels.
Earnings Schedule: Benitec Biopharma Inc. is expected to release its next earnings report on Sept. 28, 2026. The market consensus estimate for Forward EPS is -9.42.
Investor FAQ
Does Benitec Biopharma Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Benitec Biopharma Inc.?
Benitec Biopharma Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Sept. 28, 2026. The company currently has a trailing EPS of -0.93.
Company Profile
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
| Year | Total Dividends |
|---|---|
| ▸2018 |
0.77 USD
|
| June 8, 2018 | 0.0030 |
| June 8, 2018 | 0.7650 |
| Split Date | Split Ratio to 1 |
|---|---|
| June 16, 2015 | 1:4 |
| Nov. 18, 2019 | 1:10 |
| April 15, 2020 | 0.67 |
| July 26, 2023 | 0.06 |
Community Discussion